Home Newsfeeds Baird Maintains Outperform on Paycor HCM, Raises Price Target to $39

Baird Maintains Outperform on Paycor HCM, Raises Price Target to $39

Baird analyst Mark Marcon maintains Paycor HCM (NASDAQ:PYCR) with a Outperform and raises the price target from $37 to $39.

byBenzinga Newsdesk

August 24, 2022

1 minute read

Baird analyst Mark Marcon maintains Paycor HCM (NASDAQ:PYCR) with a Outperform and raises the price target from $37 to $39.

Morgan Stanley Maintains Equal-Weight on Wolfspeed, Raises Price Target to $106

By Benzinga Newsdesk

August 18, 9:47 AM

Morgan Stanley analyst Joseph Moore maintains Wolfspeed (NYSE:WOLF) with a Equal-Weight and raises the price target from $101 to $106.

WOLF

Aerovate Therapeutics To Present Patient Baseline Characteristics Of The Phase 2b Portion Of The Phase 2b/Phase 3 IMPAHCT Trial At The American Thoracic Society 2024 International Conference

By Benzinga Newsdesk

March 27, 9:28 AM

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster

AVTE

Needham Maintains Buy on Conmed, Lowers Price Target to $90

By Benzinga Newsdesk

October 14, 5:27 AM

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $123 to $90.

CNMD

S&P Settles Almost Flat; Market Volatility Drops

By Lisa Levin

May 9, 6:02 AM

The S&P 500 closed mostly flat on Monday after recording sharp gains in the previous session ahead of key inflation readings this week.

CTLT

Baird Maintains Outperform on Paycor HCM, Raises Price Target to $39

Related Posts

Morgan Stanley Maintains Equal-Weight on Wolfspeed, Raises Price Target to $106

Aerovate Therapeutics To Present Patient Baseline Characteristics Of The Phase 2b Portion Of The Phase 2b/Phase 3 IMPAHCT Trial At The American Thoracic Society 2024 International Conference

Needham Maintains Buy on Conmed, Lowers Price Target to $90

S&P Settles Almost Flat; Market Volatility Drops